Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation. - Wikidata - wikimedia - TriplyDB

Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation.

Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation.

http://www.wikidata.org/entity/Q34528284

about

ALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia.Activation of integrin-ERBB2 signaling in undifferentiated thyroid cancer.A single nucleotide polymorphism associated with isolated cleft lip and palate, thyroid cancer and hypothyroidism alters the activity of an oral epithelium and thyroid enhancer near FOXE1 Inhibition of STAT3 activity delays obesity-induced thyroid carcinogenesis in a mouse model.Mouse models of thyroid cancer: A 2015 update.Downregulation of Notch-regulated Ankyrin Repeat Protein Exerts Antitumor Activities against Growth of Thyroid Cancer.SAHA-induced loss of tumor suppressor Pten gene promotes thyroid carcinogenesis in a mouse model Metformin blocks progression of obesity-activated thyroid cancer in a mouse model.Inhibition of STAT3 signaling blocks obesity-induced mammary hyperplasia in a mouse model.Modeling anaplastic thyroid carcinoma in the mouse.Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.Epigenetic Modifications: Novel Therapeutic Approach for Thyroid Cancer cMYC expression in thyroid follicular cell-derived carcinomas: a role in thyroid tumorigenesis.Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model.Metabolic Alterations of Thyroid Cancer as Potential Therapeutic Targets.Integrated microRNA-mRNA analyses of distinct expression profiles in follicular thyroid tumors.Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer.Metabolic Reprogramming in Thyroid Carcinoma.Mouse Model of Poorly Differentiated Thyroid Carcinoma Driven by STRN-ALK Fusion Synergistic effects of BET and MEK inhibitors promote regression of anaplastic thyroid tumors

P2860

Q33687080-957F21D5-4F72-40E5-8DA1-F6B5DD40C607 Q34704914-A35EB675-D13A-4712-B57C-C8075EEE10F7 Q35766367-CAF96FBC-5BC8-43B1-9695-F70388484F27 Q36351206-C8E00B9F-0046-4A74-A0F3-A7F539D73BAD Q36405539-6B4C73B6-C974-4209-B947-421DAAFE808C Q37061023-6F4EECEC-BE3D-458B-AAB2-EA5755BB3A50 Q37123127-D53D2C76-CB2A-4ECA-A3D0-A9D9E5AD6E7C Q37376404-1424070B-C64D-44D3-BD44-6EF50B42A8A7 Q37743533-1B69A5D3-6C57-4A9A-A19A-3505BA507BCF Q38270915-B65F494F-14F5-4E67-9A6F-F24408D11942 Q41418283-6AE1211E-2623-4576-90B0-242188FDBC40 Q42101746-2BAF84F9-5EA7-4E1E-AAEC-6BB64FFDDB46 Q42281151-483154CF-7C68-4FFE-858F-2A80939A4E0C Q42694831-88CE622D-80AC-4CD3-A52F-660CA78C38DF Q47124483-694911F3-59C4-443E-944A-A6FB6E4052F1 Q47552152-A4118926-BA64-4884-AF89-0D1D17F5C8B1 Q51075677-7143588F-EC2F-4E50-A5AD-F43FDB2010B8 Q53697345-E3F0C189-C12C-4DE8-94B8-5D84EAD1B5D6 Q58701147-BB1B1973-9055-4C1A-B458-31AB0417C0C3 Q59136532-6E8DEB9D-1E79-49DB-A79C-84022D752AB3

P2860

Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation.

http://www.wikidata.org/entity/Q34528284

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Synergistic signaling of KRAS ...... cer through MYC up-regulation.

@ast

Synergistic signaling of KRAS ...... cer through MYC up-regulation.

@en

Synergistic signaling of KRAS ...... cer through MYC up-regulation.

@nl

type

label

Synergistic signaling of KRAS ...... cer through MYC up-regulation.

@ast

Synergistic signaling of KRAS ...... cer through MYC up-regulation.

@en

Synergistic signaling of KRAS ...... cer through MYC up-regulation.

@nl

prefLabel

Synergistic signaling of KRAS ...... cer through MYC up-regulation.

@ast

Synergistic signaling of KRAS ...... cer through MYC up-regulation.

@en

Synergistic signaling of KRAS ...... cer through MYC up-regulation.

@nl

P1433

Q34528284-868BDDC3-0C36-4D7E-95EA-045E12A66E16

P1476

Q34528284-2A65AB46-9740-4DBF-93AB-6146D2406D26

P2093

Q34528284-1000A5D5-FDDE-4E9D-9135-81CE427AA538

Q34528284-1679FAC9-A16B-4D7E-B5F8-A011FA3CF061

Q34528284-A3F49236-B1FB-47E8-BCAC-EBED94190310

Q34528284-BEC28947-074F-40E3-A419-95020E784308

Q34528284-C91CE1B3-DA75-4008-AD3D-E28756E8AC77

P2860

Q34528284-0222E9A2-5488-4991-A4B4-DC15DD366DEF

Q34528284-0986E20F-24D2-4390-ACC4-5752B3DB21AF

Q34528284-0B8E3D1C-F2CF-4C6D-99A6-0E51F1EE7CF2

Q34528284-11E51148-9553-4A9B-AC96-5F0813C9EA51

Q34528284-2EF51DCF-181E-4D60-B40B-20994A871A4F

Q34528284-3259ADF0-4227-44D7-8373-E16D3DAC9BE1

Q34528284-35CAA092-1462-4A1F-B99C-9F16C68263F9

Q34528284-387DBEC3-0785-4A4F-B743-A893B63145D9

Q34528284-3C52AFC1-EE62-48AC-8D0F-BFCA9C1634F1

Q34528284-44FE3705-E2A3-4BDA-BD7A-B4961EF3E03D

P304

Q34528284-BA48E7DA-E8EB-46A0-9E49-D6EB61FEAEAC

P31

Q34528284-32A3CB0A-E961-42A7-B5F4-FBF09B7B1DDB

P356

Q34528284-9FFCBDA1-F2B2-4D27-92D7-DF98D076829B

P433

Q34528284-F27F23F3-6202-4645-92DA-E8F0344A7C4E

P478

Q34528284-D1B10DF9-CFAF-4F8A-B609-D38B1926BF1E

P577

Q34528284-19C46749-B0CD-42AF-9271-2BCC573639DB

P5875

Q34528284-25633ED8-EC12-4813-9EA8-F356CDBFE2EB

P698

Q34528284-589D023C-3436-47D5-886B-3B33BF1FEC95

P932

Q34528284-882AE7C6-1F9F-41EE-B19B-1656E5E15017

P356

J.NEO.2014.08.003

P1433

P1476

Synergistic signaling of KRAS ...... cer through MYC up-regulation.

@en

P2093

Jeong Won Park

http://www.w3.org/2001/XMLSchema#string

Li Zhao

http://www.w3.org/2001/XMLSchema#string

Mark C Willingham

http://www.w3.org/2001/XMLSchema#string

Sheue-Yann Cheng

http://www.w3.org/2001/XMLSchema#string

Xuguang Zhu

http://www.w3.org/2001/XMLSchema#string

P2860

Selective inhibition of BET bromodomains

Characterization of seven novel mutations of the c-erbA beta gene in unrelated kindreds with generalized thyroid hormone resistance. Evidence for two "hot spot" regions of the ligand binding domain

Management of differentiated thyroid cancer in the presence of resistance to thyroid hormone and TSH-secreting adenomas: a report of four cases and review of the literature

Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors

The Myc/Max/Mad network and the transcriptional control of cell behavior

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

Reprogramming of human somatic cells to pluripotency with defined factors

The landscape of somatic copy-number alteration across human cancers.

Selective inhibition of tumor oncogenes by disruption of super-enhancers

c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations.

P304

757-769

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NEO.2014.08.003

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2014-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265854333

http://www.w3.org/2001/XMLSchema#string

P698

25246276

http://www.w3.org/2001/XMLSchema#string

P932

4234871

http://www.w3.org/2001/XMLSchema#string